Alentis Therapeutics
Updated: February 16, 2026
CEO Roberto Iacone
Country: Switzerland | Funding: $365.4M (+)
Website: https://alentis.ch/
ALENTIS Therapeutics develops novel therapeutics for the treatment of advanced liver fibrosis and liver cancer. The company is developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies against its therapeutic target, claudin-1. Its unique antibodies specifically target exposed claudin-1 to open the rigid extracellular matrix, block disease signals and, in cancer, selectively kill tumor cells. ALENTIS's clinical candidates include the ADC ALE.P02 for the treatment of squamous cell carcinomas and the monoclonal antibody lixudebart for the treatment of organ fibrosis. In addition to clinical development, its preclinical programs include other anti-claudin-1 therapies, including other ADCs.
Website: https://alentis.ch/
ALENTIS Therapeutics develops novel therapeutics for the treatment of advanced liver fibrosis and liver cancer. The company is developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies against its therapeutic target, claudin-1. Its unique antibodies specifically target exposed claudin-1 to open the rigid extracellular matrix, block disease signals and, in cancer, selectively kill tumor cells. ALENTIS's clinical candidates include the ADC ALE.P02 for the treatment of squamous cell carcinomas and the monoclonal antibody lixudebart for the treatment of organ fibrosis. In addition to clinical development, its preclinical programs include other anti-claudin-1 therapies, including other ADCs.
